Neurocrine Biosciences, Inc.’s recently made public that its Chief Commercial Officer BENEVICH ERIC unloaded Company’s shares for reported $2.64 million on Apr 15 ’24. In the deal valued at $133.36 per share,19,818 shares were sold. As a result of this transaction, BENEVICH ERIC now holds 40,778 shares worth roughly $5.84 million.
Then, Delaet Ingrid sold 272 shares, generating $37,346 in total proceeds. Upon selling the shares at $137.30, the Chief Regulatory Officer now owns 7,507 shares.
Before that, Delaet Ingrid sold 5,000 shares. Neurocrine Biosciences, Inc. shares valued at $725,320 were divested by the Chief Regulatory Officer at a price of $145.06 per share. As a result of the transaction, Delaet Ingrid now holds 7,507 shares, worth roughly $1.07 million.
Wells Fargo upgraded its Neurocrine Biosciences, Inc. [NBIX] rating to an Overweight from a an Equal weight in a research note published on April 24, 2024; the price target was increased to $170 from $140. Deutsche Bank began covering NBIX with “Buy” recommendation on December 12, 2023.
Price Performance Review of NBIX
On Tuesday, Neurocrine Biosciences, Inc. [NASDAQ:NBIX] saw its stock jump 1.04% to $143.19. Over the last five days, the stock has gained 4.11%. Neurocrine Biosciences, Inc. shares have risen nearly 8.67% since the year began. Nevertheless, the stocks have risen 47.01% over the past one year. While a 52-week high of $148.37 was reached on 03/21/24, a 52-week low of $89.04 was recorded on 02/07/24. SMA at 50 days reached $137.60, while 200 days put it at $122.92. A total of 0.66 million shares were traded, compared to the trading of 0.5 million shares in the previous session.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 141.44, which if violated will result in even more drops to 139.69. On the upside, there is a resistance level at 144.40. A further resistance level may holdings at 145.61. The Relative Strength Index (RSI) on the 14-day chart is 59.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.59, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 13.45%. Stochastics %K at 77.80% indicates the stock is a holding.
The most recent change occurred on August 21, 2023 when Mizuho resumed its ‘”a Neutral”‘ rating for the stock and retained the price target to $113.
